JP2011524906A5 - - Google Patents

Download PDF

Info

Publication number
JP2011524906A5
JP2011524906A5 JP2011514619A JP2011514619A JP2011524906A5 JP 2011524906 A5 JP2011524906 A5 JP 2011524906A5 JP 2011514619 A JP2011514619 A JP 2011514619A JP 2011514619 A JP2011514619 A JP 2011514619A JP 2011524906 A5 JP2011524906 A5 JP 2011524906A5
Authority
JP
Japan
Prior art keywords
fluoro
phenyl
thiazolo
pyridin
phenylcyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011514619A
Other languages
English (en)
Japanese (ja)
Other versions
JP5571073B2 (ja
JP2011524906A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/003666 external-priority patent/WO2009154775A1/en
Publication of JP2011524906A publication Critical patent/JP2011524906A/ja
Publication of JP2011524906A5 publication Critical patent/JP2011524906A5/ja
Application granted granted Critical
Publication of JP5571073B2 publication Critical patent/JP5571073B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011514619A 2008-06-20 2009-06-18 S1p1受容体作働薬およびその使用 Expired - Fee Related JP5571073B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7447608P 2008-06-20 2008-06-20
US61/074,476 2008-06-20
PCT/US2009/003666 WO2009154775A1 (en) 2008-06-20 2009-06-18 S1p1 receptor agonists and use thereof

Publications (3)

Publication Number Publication Date
JP2011524906A JP2011524906A (ja) 2011-09-08
JP2011524906A5 true JP2011524906A5 (enExample) 2012-08-02
JP5571073B2 JP5571073B2 (ja) 2014-08-13

Family

ID=41434357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011514619A Expired - Fee Related JP5571073B2 (ja) 2008-06-20 2009-06-18 S1p1受容体作働薬およびその使用

Country Status (10)

Country Link
US (2) US7842685B2 (enExample)
EP (1) EP2306994B1 (enExample)
JP (1) JP5571073B2 (enExample)
AR (1) AR072185A1 (enExample)
AU (1) AU2009260726B2 (enExample)
CA (1) CA2728046A1 (enExample)
ES (1) ES2433579T3 (enExample)
MX (1) MX2010013555A (enExample)
TW (1) TW201000099A (enExample)
WO (2) WO2009154775A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33178A (es) * 2010-01-13 2011-08-31 Sanofi Aventis Derivados de ácido carboxílico heteroxíclicos que comprenden un anillo de oxazolopirimidina 2, 5, 7-sustituido
TWI485153B (zh) * 2010-01-13 2015-05-21 Sanofi Aventis 2,5,7-經取代唑并嘧啶衍生物
TWI478929B (zh) * 2010-01-13 2015-04-01 Sanofi Aventis 含2,5,7-經取代唑并嘧啶環之羧酸衍生物
JP5841068B2 (ja) * 2010-01-14 2016-01-06 サノフイ 2,5−置換されたオキサゾロピリミジン環を有する複素環式カルボン酸誘導体
PT2523962E (pt) * 2010-01-14 2014-02-06 Sanofi Sa Derivados de ácidos carboxílicos com um anel oxazolopirimidina substituído em 2,5
MX2012007837A (es) * 2010-01-14 2012-07-30 Sanofi Sa Derivados de oxazolopirimidina 2, 5 - sustituidos.
TW201206429A (en) * 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
TW201217387A (en) 2010-09-15 2012-05-01 Hoffmann La Roche Azabenzothiazole compounds, compositions and methods of use
JP5999387B2 (ja) * 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Crth2拮抗薬としてのピラゾール化合物
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
US8735402B2 (en) * 2011-07-07 2014-05-27 Sanofi Cycloalkyloxycarboxylic acid derivatives
WO2013158422A1 (en) 2012-04-17 2013-10-24 E. I. Du Pont De Nemours And Company Heterocyclic compounds for controlling invertebrate pests
JP6021915B2 (ja) * 2012-07-20 2016-11-09 三菱電機株式会社 保持フレームおよび太陽電池モジュール
HK1212699A1 (zh) 2013-02-20 2016-06-17 拜耳医药股份公司 作为mknk1抑制剂的取代的咪唑并[1,2-b]哒嗪类化合物
AU2014308991B2 (en) 2013-08-21 2019-02-14 Janssen Biopharma, Inc. Antiviral compounds
WO2016182850A1 (en) 2015-05-08 2016-11-17 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
JP7252908B2 (ja) * 2017-06-14 2023-04-05 トレベナ・インコーポレイテッド S1p1活性を調節するための化合物およびその使用法
CN110256466A (zh) * 2019-07-31 2019-09-20 昆山迪安医学检验实验室有限公司 一种噻唑[5,4-b]-吡啶基生物活性化合物的制备方法及其抗肿瘤活性的检测
MX2022005766A (es) * 2019-11-19 2022-08-08 Trevena Inc Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1).
CN115611793A (zh) * 2021-07-14 2023-01-17 山东新华制药股份有限公司 硫代酰胺类化合物的合成方法
CN116410213A (zh) * 2023-02-21 2023-07-11 武汉大学 一种合成3-碳基-1-硼基环类化合物的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
ATE420869T1 (de) 2000-10-05 2009-01-15 Takeda Pharmaceutical Promotoren zur proliferation und differenzierung von stammzellen und/oder vorstufen von neuronenzellen
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
EP1460067A4 (en) 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Edg受容体作動薬
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
MXPA05011597A (es) * 2003-04-30 2005-12-15 Novartis Ag Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina.
CL2004001120A1 (es) * 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
EP2402323A3 (en) 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
EP1965807A4 (en) 2005-11-23 2010-10-27 Epix Delaware Inc S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE
US7919519B2 (en) * 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
US20090182003A1 (en) 2006-01-13 2009-07-16 President And Fellows Of Harvard College Methods and Compositions for Treatment Cell Proliferative Disorders
JP2009526761A (ja) 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
EP1987396B1 (en) 2006-02-08 2010-05-26 Kodak Graphic Communications GmbH Uv-sensitive lithographic printing plate precursor with benzoxazole derivative and analogues thereof as sensitizer
AU2007227274A1 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. S1P receptor modulating compounds
US7989472B2 (en) * 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2010510245A (ja) 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション 抗ウイルス化合物
WO2008073865A2 (en) 2006-12-11 2008-06-19 Novartis Ag Method of preventing or treating myocardial ischemia
JP5191497B2 (ja) * 2007-03-21 2013-05-08 エピックス ファーマシューティカルズ,インコーポレイテッド S1p受容体調節化合物およびその使用
JP2008308448A (ja) 2007-06-15 2008-12-25 Sankyo Agro Kk (3−硫黄原子置換フェニル)へテロアリール誘導体
AU2008302746B2 (en) 2007-09-20 2014-07-03 Amgen Inc. 1-(4-(benzylbenzamid0) -benzyl) azetidine-3-carboxylic acid derivatives and related compounds as SlP receptor modulators for the treatment of immune disorders

Similar Documents

Publication Publication Date Title
JP2011524906A5 (enExample)
JP2013527202A5 (enExample)
JP2013512900A5 (enExample)
HRP20120144T1 (en) Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
JP2013512899A5 (enExample)
JP2014502979A5 (enExample)
JP2012508734A5 (enExample)
JP2011500697A5 (enExample)
JP2020506171A5 (enExample)
RU2012127760A (ru) Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний
JP2013531028A5 (enExample)
JP2014526549A5 (enExample)
JP2004525179A5 (enExample)
NZ597241A (en) Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
JP2006504656A5 (enExample)
NZ626985A (en) Combination therapy (vemurafenib and a mdm2 inhibitor) for the treatment proliferative disorders
NZ590839A (en) Treatment of pulmonary arterial hypertension
EA016687B8 (ru) Производные циклопропиламида
NZ598083A (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
JP2021528387A5 (enExample)
JP2007502265A5 (enExample)
JP2009532438A5 (enExample)
JP2010533131A5 (enExample)
PH12021550170A1 (en) Pharmaceutical dosage form which can be adminitered orally and has modified release